genetesis

Mithril Capital-led Series C to launch 5-minute noninvasive ischemia assessment requiring no pharmaceuticals, no exercise, and no radiation. MASON, Ohio (BUSINESS WIRE) Genetesis, the market leader in next-generation biomagnetic imaging, has announced that it has closed $17.5 million in Series... Read More →

Genetesis, the market leader in the design, development and commercialization of biomagnetic imaging solutions, today announced its new Scientific Advisory Board (SAB). Read More →

CardioFlux®, the most advanced commercially available magnetocardiograph (MCG), leverages highly sensitive room temperature magnetometers to deliver noninvasive measurement of the heart’s naturally-generated magnetic fields. Read More →

Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFluxTM imaging, today announced several important updates. The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. The round included participation by return investors CincyTech, Ohio Innovation Fund and Mark Cuban. Read More →

“TDK’s rich history in magnetics and its recent breakthroughs in biomagnetics at picoTesla levels makes them one of our strongest partners to date,” said Peeyush Shrivastava, CEO and founder of Genetesis. “We are committed to bring the most accurate diagnostics that can assist emergency physicians and cardiologists in making the best decisions for cardiac health in a non-invasive and rapid fashion. We are elated to have TDK as our strategic partner because of their pioneering work in magnetic materials and its commercialization. Their recent leadership around supporting frontier-tech entrepreneurs caught our attention and we are excited about this next chapter.” Read More →

A 90-second chest scan could be a game-changer for triaging patients who present to the emergency department with undiagnosed chest pain, according to research out of Detroit. Writing in the International Journal of Cardiology: Heart and Vasculature, lead author Margarita Pena,... Read More →

(Mason, OH March 22, 2019 8 am) Genetesis, a medical technology company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has received FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the... Read More →

Genetesis, a Mason startup that’s developing a medical imaging device that could benefit patients with heart problems, raised $7.5 million in a Series A round of funding from a group of investors that includes CincyTech and billionaire Mark Cuban of the TV show “Shark Tank.”